We hypothesized that due to changes in barrier integrity and molecular sizing, lower SP-D levels in BAL would be associated with higher concentrations of SP-D in serum in smokers and especially in COPD patients. This evidence concerns the gene SFTPD and chronic obstructive pulmonary disease.